Jasper Bos
CIK: 0001897789
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
About Bos Jasper
Bos Jasper (SEC CIK 0001897789) files insider reports with the SEC as Director of Braveheart Bio, Inc. (BRVE) and Director of enGene Holdings Inc. (ENGN).
Signal8 holds 3 ownership filings by Bos Jasper (1 Form 3, 2 Form 4), filed between Jun 16, 2025 and Aug 7, 2026. Those filings report 2 transactions, from Jun 16, 2025 to Aug 5, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Bos Jasper's filings is in SAN FRANCISCO, CA.
Recent filings by Bos Jasper
Other insiders filing for Braveheart Bio, Inc. (BRVE)
- Agarwala Vineeta, Director
- AH Bio Fund IV, L.P., 10% Owner
- Chimovits Erez, Director
- ORBIMED ADVISORS LLC, Director
- Jiangsu Hengrui Pharmaceuticals Co., Ltd., 10% Owner
- Forbion Growth Opportunities Fund III Cooperatief U.A., 10% Owner